Blockchain Registration Transaction Record

Oncotelic Taps IBN for Strategic Communications Amid Cancer Drug Development

Oncotelic Therapeutics partners with IBN for corporate communications as it advances Phase 3 cancer drug OT-101 and RNA-based immunotherapies for rare diseases.

This development matters because Oncotelic's work addresses some of the most challenging cancers and rare pediatric diseases where treatment options are severely limited. The company's Phase 3 trial for pancreatic ductal adenocarcinoma targets one of the deadliest cancers with a five-year survival rate of just 10%. Their RNA-based immunotherapy approach represents a potentially groundbreaking advancement in cancer treatment. For patients and families facing these devastating diagnoses, Oncotelic's research could mean new hope and life-extending treatments. Additionally, the enhanced communications strategy through IBN increases transparency and investor awareness, which is crucial for securing funding to advance these potentially life-saving therapies through clinical trials and ultimately to patients in need.